Elisabet Gregori Puigjane

Title: Elisabet Gregori Puigjane: Innovator in Neurodegenerative Disease Treatment

Introduction

Elisabet Gregori Puigjane is a notable inventor based in Alcobendas, Spain. She has made significant contributions to the field of medicine, particularly in the treatment of neurodegenerative illnesses. Her innovative work has the potential to impact the lives of many individuals suffering from these conditions.

Latest Patents

Elisabet holds a patent for a compound that inhibits the activation of the enzyme Erk 1/2, which is crucial in the treatment of neurodegenerative diseases. The patent describes a compound of formula (I) that is intended for use as a medicine, specifically targeting diseases mediated by the activation of the protein kinase Erk1/2. This includes conditions such as Alzheimer's disease, related dementia, epilepsy, Parkinson's disease, Huntington's disease, and stroke. The compound effectively inhibits the activation of Erk1/2 induced by tissue plasminogen activator (TPA) and also prevents apoptosis generated by the β-amyloid peptide. She has 1 patent to her name.

Career Highlights

Elisabet is currently associated with Farmalider, S.A., where she continues her research and development efforts. Her work is characterized by a commitment to advancing medical science and improving treatment options for patients with neurodegenerative diseases.

Collaborations

Elisabet collaborates with esteemed colleagues, including Pilar Navarro Medrano and Marisol Montolio Del Olmo. These partnerships enhance her research capabilities and contribute to the innovative environment at Farmalider.

Conclusion

Elisabet Gregori Puigjane is a pioneering inventor whose work in developing treatments for neurodegenerative diseases holds promise for many patients. Her contributions to medical science are invaluable and reflect her dedication to improving health outcomes.